Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring
Posted inCardiology General Surgery news

Standardized DOAC Interruption Protocols Result in Low Residual Levels, but Apixaban and Renal Impairment Merit Closer Monitoring

The DALI cohort study reveals that while current DOAC interruption protocols are generally effective, 13.1% of apixaban users maintain levels ≥30 ng/mL before surgery. However, these residual levels did not correlate with increased surgical blood loss, suggesting other factors drive perioperative bleeding.
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
Posted inHematology-Oncology Internal Medicine news

Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia

The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thrombocytopenia (ITP) compared to eltrombopag alone.